Evidence map›Paper›PMID 41595222›Full record

ReviewCancers2026

Quantitative Imaging Advances in HPV-Positive Oropharyngeal Carcinoma.

Dermot Farrell, Houda Bahig, Richard Khor, Luiz P Kowalski, Remco de Bree, Avraham Eisbruch, Heleen Bollen, Fernando Lopez, M P Sreeram, Orlando Guntinas-Lichius and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Dermot FarrellDepartment of Radiation Oncology, Austin Health, Melbourne, VIC 3084, Australia.
Houda BahigDepartment of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, Montreal, QC H2X 0C1, Canada.
Richard KhorDepartment of Radiation Oncology, Austin Health, Melbourne, VIC 3084, Australia.
Luiz P KowalskiDepartment of Head and Neck Surgery and Otorhinolaryngology, A.C. Camargo Cancer Center, São Paulo 01509-010, Brazil.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.ORCID 0000-0001-7128-5814
Avraham EisbruchDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Heleen BollenLaboratory of Experimental Radiotherapy, Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.
Fernando LopezENT and Head and Neck Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.ORCID 0000-0001-7019-9746
M P SreeramDepartment of Head and Neck Oncology, Sri Shankara Cancer Hospital and Research Centre, Bangalore 560004, India.ORCID 0000-0002-4050-9106
Orlando Guntinas-LichiusDepartment of Otorhinolaryngology, Jena University Hospital, Am Klinikum 1, D-07747 Jena, Germany.ORCID 0000-0001-9671-0784
Juan P RodrigoDepartment of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, 33011 Oviedo, Spain.ORCID 0000-0003-3063-0890
Nabil F SabaDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-4972-1477
Karthik N RaoDepartment of Head and Neck Oncology, Sri Shankara Cancer Hospital and Research Centre, Bangalore 560004, India.
Sandra NuytsDepartment of Radiation Oncology, University Hospitals Leuven, KU Leuven-University of Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5540-4796
Anna Luíza Damaceno AraújoHead and Neck Surgery Department and LIM 28, University of São Paulo Medical School and Hospital Israelita Albert Einstein, São Paulo 05508-020, Brazil.ORCID 0000-0002-3725-8051
Alfio FerlitoInternational Head and Neck Scientific Group, 35100 Padua, Italy.ORCID 0000-0002-8247-8002
Sweet Ping NgDepartment of Radiation Oncology, Austin Health, Melbourne, VIC 3084, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HPV-positive OPSCC shows a favourable prognosis, prompting evaluation of de-escalated and adaptive strategies. Quantitative imaging may provide scalable biomarkers to individualise care. Quantitative imaging can support baseline risk stratification, early on-treatment decision-making, and posttreatment surveillance in HPV-positive OPSCC. Real-world translation requires standardised reporting, calibration/harmonisation across centres, rigorous model validation, and workflow integration with radiotherapy planning. Quantitative MRI, CT, and PET, augmented by radiomics and AI, show convergent promise as non-invasive biomarkers to enable safe individualisation of therapy in HPV-positive OPSCC, contingent on methodological rigour and prospective, externally validated studies. Despite this promise, clinical translation faces substantial barriers, including limited external validation, heterogeneous methodologies, and the need for standardised, prospectively validated pipelines.

Indexed as

CTHPVMRIoropharyngealPETradiomics

Identifiers

PMID41595222
PMCPMC12839270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.